Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 1.00 |
| ▸ | SRC | P12931 | 14/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 12/20 | 1.00 |
| ▸ | FYN | P06241 | 8/20 | 1.00 |
| ▸ | HCK | P08631 | 6/20 | 0.82 |
| ▸ | BLK | P51451 | 6/20 | 0.82 |
| ▸ | LYN | P07948 | 6/20 | 0.82 |
| ▸ | LCK | P06239 | 6/20 | 0.82 |
| ▸ | YES1 | P07947 | 5/20 | 0.82 |
| ▸ | FGR | P09769 | 5/20 | 0.82 |
| ▸ | FRK | P42685 | 6/20 | 0.79 |
| ▸ | KIT | P10721 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.63 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.63 |
| ▸ | BACE1 | P56817 | 1/20 | 0.63 |
| ▸ | PRKDC | P78527 | 1/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18258375 | 1.00 | ABL1 (1.00) | ABL1SRCPTK6FYNHCK | |
| Fumaric Acid SCHEMBL31543001 | 0.96 | SRC (0.92) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL26148156 | 0.96 | ABL1 (0.92) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL18258328 | 0.95 | ABL1 (0.91) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL18258370 | 0.92 | SRC (0.85) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL18258331 | 0.92 | ABL1 (1.00) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL18258351 | 0.91 | PTK6 (1.00) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL25030590 | 0.91 | ABL1 (0.85) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL30183417 | 0.91 | ABL1 (0.85) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL26148157 | 0.91 | ABL1 (0.83) | ABL1SRCPTK6FYNHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20250241916-A1 | TYROSINE KINASE INHIBITORS | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-07-31 | — | — | US | claimed |
| WO-2025056601-A1 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING KINASE INHIBITOR AND AUTOPHAGY INDUCER AND USES THEREOF | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2025-03-20 | — | — | WO | claimed |
| WO-2024182413-A1 | THERAPEUTIC METHODS | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-09-06 | — | — | WO | claimed |
| EP-4188380-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2023-06-07 | — | — | EP | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4729067-A2 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS WITH A SHEET OF ANISOTROPIC MATERIAL | Novocure GmbH (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | disclosed |
| EP-4384518-B1 | TYROSINE KINASE INHIBITORS | UNIV COURT UNIV OF EDINBURGH (GB) | 2025-12-17 | — | — | EP | disclosed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-25 | — | — | US | disclosed |
| WO-2023017264-A1 | TYROSINE KINASE INHIBITORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2023-02-16 | — | — | WO | disclosed |
| US-20230037806-A1 | Electrode Assembly for Applying Tumor Treating Fields (TTFields) with a Sheet of Anisotropic Material | NOVOCURE GMBH (CH) | 2023-02-09 | — | — | US | disclosed |
| WO-2023012707-A1 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS (TTFIELDS) WITH A SHEET OF ANISOTROPIC MATERIAL | NOVOCURE GMBH (CH) | 2023-02-09 | — | — | WO | disclosed |
| EP-4117718-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022197857-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NUCLEOTIDE REPEAT EXPANSION | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | disclosed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | CTTN, SRC, FYN | ABL1 6/4885SRC 2/4885PTK6 307/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | ABL1 751/4885SRC 10/4885PTK6 330/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | ABL1 939/4885SRC 809/4885PTK6 3006/4885 |
| US-20250241916-A1 | TYROSINE KINASE INHIBITORS | BTK, ABL1, LCK | ABL1 2/4885SRC 6/4885PTK6 78/4885 |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | BRAF, MAP2K1, MOK | ABL1 876/4885SRC 119/4885PTK6 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.